SCHEMBL8620374

SCHEMBL8620374

O=C(O)Cc1ccc(O)cc1Br

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CAMK2A Q9UQM7 6/20 0.51
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
GLA P06280 1/20 0.49
CYP2C9 P11712 1/20 0.49
HPGD P15428 1/20 0.49
TSHR P16473 1/20 0.49
NFKB1 P19838 1/20 0.49
PMP22 Q01453 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
CA2 P00918 1/20 0.47
AKR1B1 P15121 2/20 0.46
LCK P06239 1/20 0.46
FYN P06241 1/20 0.46
GRB2 P62993 1/20 0.46
EGFR P00533 2/20 0.45
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30745400 1.00 CAMK2A (0.51) CAMK2AALDH1A1LMNAGLACYP2C9
SCHEMBL1644783 0.84 EGFR (0.49) CAMK2AALDH1A1LMNAGLACYP2C9
SCHEMBL10479066 0.82 PTGDR2 (0.42) ALDH1A1LMNAGLACYP2C9HPGD
SCHEMBL29710650 0.82 PTGDR2 (0.42) ALDH1A1LMNAGLACYP2C9HPGD
SCHEMBL156238 0.81 TYR (0.60) CAMK2AALDH1A1LMNAGLACYP2C9
SCHEMBL29419312 0.81 TYR (0.60) CAMK2AALDH1A1LMNAGLACYP2C9
SCHEMBL27743914 0.81 POLB (0.50) NPSR1POLB
SCHEMBL4047837 0.78 KEAP1 (0.50) CAMK2ACYP2C9AKR1B1
SCHEMBL909444 0.78 PKM (0.53) TSHRAKR1B1
SCHEMBL2729900 0.78 HPGD (0.42) CAMK2AALDH1A1LMNACYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104447646-B A kind of method complete synthesis for natural product Moracin M 中科院广州化学有限公司 2016-08-31 CN claimed
EP-4692059-A1 CATIONIC LIPID HAVING DISULFIDE BOND Tohoku University (JP) 2026-02-11 EP disclosed
EP-4461355-A2 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE Carmot Therapeutics, Inc. (US) 2024-11-13 EP disclosed
WO-2024203577-A1 CATIONIC LIPID HAVING DISULFIDE BOND 国立大学法人東北大学 2024-10-03 WO disclosed
US-20240262811-A1 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE CARMOT THERAPEUTICS, INC. 2024-08-08 US disclosed
EP-4334304-A1 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE Carmot Therapeutics, Inc. (US) 2024-03-13 EP disclosed
CN-117545748-A Benzimidazolyl GLP-1GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods of use thereof 卡莫特医疗有限公司 2024-02-09 CN disclosed
CN-115181082-B Synthetic method of natural molecule Moracin M 江苏集萃分子工程研究院有限公司 2023-11-03 CN disclosed
CN-113121485-B 3-aryl coumarin derivative and preparation method and application thereof 中山大学 2023-01-03 CN disclosed
US-20220396569-A1 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE CARMOT THERAPEUTICS, INC. 2022-12-15 US disclosed
EP-2649062-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF ACETYL-COA CARBOXYLASE (ACC) Takeda Pharmaceutical Company Limited (JP) 2013-10-16 EP disclosed
CN-103347872-A Bicyclic compound TAKAEDA CHEMICAL IND LTD 2013-10-09 CN disclosed
WO-2012074126-A9 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-06 WO disclosed
US-20120142714-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-06-07 US disclosed
WO-2012074126-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-06-07 WO disclosed
CN-1882524-A 4- ((phenoxyalkyl) thio) -phenoxyacetic acids and analogs JANSSEN PHARMACEUTICA NV (BE) 2006-12-20 CN disclosed
EP-0582908-B1 2-Substituted quinolylmethoxy-phenylacetic acid- and -benzylacyl derivatives, process for their preparation and their use as inhibitors of leukotriene synthesis BAYER AG (DE) 1998-05-27 EP disclosed
US-5597833-A LEUKOTRIENE SYNTHESIS INHIBITORS FOR ANTIINFLAMMATORY AGENTS, RESPIRATORY SYSTEM DISORDERS, ANTIALLERGENS OR ANTIISCHEMIC AGENTS BAYER AKTIENGESELLSCHAFT (DE) 1997-01-28 US disclosed
CN-1087337-A The quinolin-2-ylmethoxy phenylacetic acid derivatives that replaces BAYER AG (DE) 1994-06-01 CN disclosed
EP-0582908-A1 2-Substituted guinolylmethoxy-phenylacetic acid derivatives, process for their preparation and their pharmaceutical use BAYER AG (DE) 1994-02-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220396569-A1 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE GLP1R, GIPR, GCGR CAMK2A 2434/4885ALDH1A1 3087/4885LMNA 1687/4885
US-20120142714-A1 BICYCLIC COMPOUND ACACA, ACACB, FABP4 CAMK2A 1494/4885ALDH1A1 172/4885LMNA 3226/4885
US-20240262811-A1 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE GLP1R, GIPR, GCGR CAMK2A 2434/4885ALDH1A1 3087/4885LMNA 1687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.